Proof Delivery Form
Please return this form with your proof

CUP reference:

Date of delivery:

Journal and Article number: ZYG 287

Volume and Issue Number: 12(3)

Colour Figures: Nil

Number of pages (not including this page): 8

ZYGOTE – ‘Return of Proofs’ instructions

We hope you have now downloaded a proof of your paper in pdf format, and also the copyright form and the offprint order form.

Please print out a proof of your paper and the two forms. Both the forms should be completed in hard copy, and corrections to your proof should also be marked on a hard copy.

Please check the proofs carefully, answering any queries. Queries raised by the typesetter are listed below: the text to which the queries refer is flagged in the margins of the proof. Please note it is your responsibility to check the factual content of your paper. Only typographical and factual errors should be corrected – you may be charged for corrections of non-typographical errors. Mark any typesetting errors in RED ink and your own (author corrections) in BLUE or BLACK ink.

If any figure requires correction of anything other than a typographical error introduced by the printer, you must provide a new copy.

Please return the corrected proof, the Copyright form and the Offprint Order Form, within three days of receipt to:-

Nicki Marshall
Production Editor (Journals)
Cambridge University Press
University Printing House
Shaftesbury Road
Cambridge CB2 2BS
United Kingdom

Please return these proofs by First Class mail or FEDEX courier (or similar) if necessary or if outside Europe. It may not be possible to take your corrections into consideration if they are not received at the appropriate time. If you have any difficulties with these proofs, please contact Nicki Marshall (details above).
Author queries:
Q1: Martino et al. (1995) is not in the References.

Typesetter queries:
T1: Disk mismatch with Msp. Disk followed.

Non-printed material:
Zygote

volume...... no.............

Offprints
25 offprints of each article will be supplied free to each first named author and sent to a single address. Please complete this form and send it to the publisher (address below) within 14 days of the date stamped on it. Please give the address to which your offprints should be sent. They will be despatched by surface mail within one month of publication. For an article by more than one author this form is sent to you as the first named. All extra offprints should be ordered by you in consultation with your co-authors.

Number of offprints required in addition to the 25 free copies

Offprints to be sent to (PRINT IN BLOCK CAPITALS) .................................................................

........................................................................................................................................................ Post/Zip Code.............

Date..................................................................Author(s)........................................................................

Article title........................................................................................................................................

All enquiries about offprints should be addressed to the publisher:
Journals Production Editor, Zygote, Journals Group, Cambridge University Press, The Edinburgh Building,
Shaftesbury Road, Cambridge CB2 2RU, UK

Charges for extra offprints

<table>
<thead>
<tr>
<th>Number of copies</th>
<th>25</th>
<th>50</th>
<th>100</th>
<th>150</th>
<th>200</th>
<th>per 50 extra</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-4 pages</td>
<td>£27.00</td>
<td>£43.50</td>
<td>£69.50</td>
<td>£95.50</td>
<td>£123.50</td>
<td>£27.00</td>
</tr>
<tr>
<td>5-8 pages</td>
<td>£48.00</td>
<td>£72.50</td>
<td>£114.00</td>
<td>£152.50</td>
<td>£197.50</td>
<td>£48.00</td>
</tr>
<tr>
<td>17-24 pages</td>
<td>£52.50</td>
<td>£80.50</td>
<td>£132.50</td>
<td>£180.50</td>
<td>£239.50</td>
<td>£52.50</td>
</tr>
<tr>
<td>extra 8 pages</td>
<td>£8.00</td>
<td>£12.50</td>
<td>£20.00</td>
<td>£28.00</td>
<td>£41.50</td>
<td>£8.00</td>
</tr>
</tbody>
</table>

Methods of payment

VAT at the local rate may be added to the above charges if paid by EU residents not registered for VAT.

If registered, please quote your VAT number, or the VAT number of any agency paying on your behalf if registered.

☐ Payment against invoice. The invoice will be sent to you after publication of your article.

☐ Cheques should be made out to Cambridge University Press.

☐ Payment by someone else. Please enclose the official order when returning this form. Or ensure that when the order is sent, it mentions the name of the journal and the article title.

☐ Payment may be made by any credit card bearing the Interbank Symbol.

Signature of card holder ..................................Amount..................................Date.................................
Card number.............................................Card expiry date...................................
Card verification number.............................

The card verification number is a 3 digit number printed on the back of your Visa or Master card, it appears after and to the right of your card number. For American Express the verification number is 4 digits, and printed on the front of your card, after and to the right of your card number.

Please advise if address registered with card company is different from above

For office use only

Reference  Sent  Acknowledged  Price  Received
transfer of copyright

Please read the notes overleaf and then complete, sign, and return this form to Dr Brian Dale, Centre for Reproductive Biology, Clinica Villa del Sole, Via Manzoni 15, Naples 80123, Italy, as soon as possible.

ZYGOTE

In consideration of the publication in ZYGOTE

of the contribution entitled: ...................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
by (all authors’ names):...........................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................

1 To be filled in if copyright belongs to you

Transfer of copyright

I/we hereby assign to Cambridge University Press, full copyright in all formats and media in the said contribution.

I/we warrant that I am/we are the sole owner or co-owners of the material and have full power to make this agreement, and that the material does not contain any defamatory matter or infringe any existing copyright.

I/we further warrant that permission has been obtained from the copyright holder for any material not in my/our copyright and the appropriate acknowledgement made to the original source. I/we attach copies of all permission correspondence.

I/we hereby assert my/our moral rights in accordance with the UK Copyrights Designs and Patents Act (1988).

Signed (tick one)  □  the sole author(s)

□  one author authorised to execute this transfer on behalf of all the authors of the above article

Name (block letters)...........................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
Institution/Company...........................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
Signature: .......................................................................................................................................................... Date: ............................................................
(Additional authors should provide this information on a separate sheet.)

2 To be filled in if copyright does not belong to you

a Name and address of copyright holder: ........................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................

b The copyright holder hereby grants to Cambridge University Press the non-exclusive right to publish the contribution in the journal and to deal with requests from third parties in the manner specified in paragraphs 3 and 5 overleaf.

(Signature of copyright holder or authorised agent) ........................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................

3 US Government exemption

I/we certify that the paper above was written in the course of employment by the United States Government so that no copyright exists.

Signature: ........................................................ Name (Block letters): .........................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................

4 Requests received by Cambridge University Press for permission to reprint this article should be sent to (see para. 4 overleaf)

Name and address (block letters) ........................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
.................................................................................................................................................................................................
Notes for contributors

1 The Journal's policy is to acquire copyright in all contributions. There are two reasons for this: (a) ownership of copyright by one central organisation tends to ensure maximum international protection against unauthorised use; (b) it also ensures that requests by third parties to reprint or reproduce a contribution, or part of it, are handled efficiently and in accordance with a general policy that is sensitive both to any relevant changes in international copyright legislation and to the general desirability of encouraging the dissemination of knowledge.

2 Two 'moral rights' were conferred on authors by the UK Copyright Act in 1988. In the UK an author's 'right of paternity', the right to be properly credited whenever the work is published (or performed or broadcast), requires that this right is asserted in writing.

3 Notwithstanding the assignment of copyright in their contribution, all contributors retain the following non-transferable rights:

- The right to (continue to) post a preprint of the contribution on their personal or departmental web page provided the first screen contains the statement that the paper has been accepted for publication in Zygote published by Cambridge University Press together with the appropriate copyright notice. On publication the full bibliographical details (volume: issue number (date), page numbers) must be inserted after the journal title.
- Subject to file availability, the right to post the contribution as published on their own or their departmental home page provided the first screen includes full bibliographical details and the appropriate copyright notice.
- The right to make hard copies of the contribution or an adapted version for their own purposes, including the right to make multiple copies for course use by their students, provided no sale is involved.
- The right to reproduce the paper or an adapted version of it in any volume of which they are editor or author. Permission will automatically be given to the publisher of such a volume, subject to normal acknowledgement.

4 We shall use our best endeavours to ensure that any direct request we receive to reproduce your contribution, or a substantial part of it, in another publication (which may be an electronic publication) is approved by you before permission is given.

5 Cambridge University Press co-operates in various licensing schemes that allow material to be photocopied within agreed restraints (e.g. the CCC in the USA and the CLA in the UK). Any proceeds received from such licenses, together with any proceeds from sales of subsidiary rights in the Journal, directly support its continuing publication.

6 It is understood that in some cases copyright will be held by the contributor's employer. If so, Cambridge University Press requires non-exclusive permission to deal with requests from third parties, on the understanding that any requests it receives from third parties will be handled in accordance with paragraphs 4 and 5 above (note that your approval and not that of your employer will be sought for the proposed use).

7 Permission to include material not in your copyright

If your contribution includes textual or illustrative material not in your copyright and not covered by fair use / fair dealing, permission must be obtained from the relevant copyright owner (usually the publisher or via the publisher) for the non-exclusive right to reproduce the material worldwide in all forms and media, including electronic publication. The relevant permission correspondence should be attached to this form.

If you are in doubt about whether or not permission is required, please consult the Permissions Controller, Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge CB2 2RU, UK. Fax: +44 (0)1223 315052.
Email: lnicol@cambridge.org.

Please make a duplicate of this form for your own records.
Cysteamine, glutathione and ionomycin treatments improve in vitro fertilization of prepubertal goat oocytes

Aixa Urdaneta, Ana Raquel Jiménez, María-Teresa Paramio, and Dolors Izquierdo
Departament de Ciència Animal i dels Aliments, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

Date submitted: 7.5.04. Date accepted: 8.7.04

Summary
The aim of this study was to improve in vitro embryo development of prepubertal goat oocytes by studying the effect of adding cysteamine to in vitro maturation medium, glutathione (GSH) to in vitro fertilization medium and ionomycin to the sperm capacitation medium. In experiment 1, we analysed the effect of 1 mM GSH added to fertilization medium of oocytes matured with 400 µM cysteamine. The control group were oocytes without cysteamine and GSH. In experiment 2, oocytes matured and fertilized in the presence of 400 µM cysteamine and 1 mM GSH, respectively, were inseminated with spermatozoa treated with ionomycin or heparin. In experiment 1, the percentages of total and normal fertilized oocytes were significantly higher for oocytes supplemented with cysteamine and GSH (40.26% and 30.20%, respectively) than for oocytes from the control group (16.66%, and 10.61%, respectively). The percentage of total embryos obtained after 7 days of culture was significantly higher in the group supplemented with cysteamine and GSH (30.62%) than in the control group (8.09%). In experiment 2, percentages of total and normal fertilized oocytes were significantly higher for the group of spermatozoa capacitated with ionomycin (52.21% and 37.17%, respectively) than with heparin (38.62% and 28.35%, respectively). After 7 days of culture, total embryo rate was significantly higher in the group of sperm capacitated with ionomycin (44.91%) than with heparin (38.69%). However, the percentage of embryos developed to the blastocyst stage was not affected by any of the treatments studied.

Keywords: Cysteamine, Glutathione, Goat, Ionomycin, Prepubertal

Introduction

In vitro matured prepubertal goat oocytes often show deficiencies after their in vitro fertilization (IVF) as indicated by a low incidence of male pronuclear formation (Martino et al., 1995; Mogas et al., 1997), which would cause a high number of haploid embryos (Villamediana et al., 2001) and a low developmental competence to the blastocyst stage (Izquierdo et al., 1999).

During fertilization, the sperm nucleus is decondensed and transformed into a male pronucleus (MPN). This transformation of the sperm nucleus during IVF has been related to the levels of intracellular glutathione (GSH) (Sutovsky & Schatten, 1997). The tripeptide glutathione (γ-glutamyl-cysteinyl-glycine) is a reducing agent that plays a number of important roles in cellular metabolism (reviewed by Knapen et al., 1999), participating in various mechanisms such as amino acid transport, DNA and protein synthesis, reduction of disulphide bonds and protection of cells against oxidative damage. During the development and maturation of the oocyte in the ovary, GSH content increases as the oocyte approaches the time of ovulation (Perrault et al., 1988). When the oocytes are in vitro matured, GSH synthesis can be stimulated by the addition of low-molecular-weight thiol compounds.

Cysteamine is a low-molecular-weight thiol which when present during in vitro maturation (IVM) increases the intracytoplasmic oocyte GSH concentration in cattle (De Matos et al., 1995; Luvoni et al., 1996; De Matos & Furnus, 2000), goat (Rodriguez et al., 2003), buffalo (Gasparrini et al., 2003) and ewes (De Matos et al., 2002). Addition of cysteamine to the IVM
medium of cattle oocytes improves in vitro blastocyst development (De Matos et al., 1995, 1996). Similar results were found in sheep (De Matos et al., 2002), buffalo (Gasparrini et al., 2000), pig (Grupen et al., 1995; Yamauchi & Nagai, 1999) and mouse (De Matos et al., 2003). Previous studies in our laboratory (Rodríguez-González et al., 2003) showed that 100 µM of cysteamine added to the IVM medium of prepubertal goat oocytes increased intracellular GSH levels and significantly improved the percentages MPN formation after IVF and embryo development. Later, Urdaneta et al. (2003) concluded that the addition of 400 µM of cysteamine to the IVM medium improved embryo development of prepubertal goat oocytes compared with 100 µM. However, the percentage of blastocysts obtained in both studies was low.

During fertilization, several researchers add GSH to the sperm preparation medium (pig: Jeong & Yang, 2001; cattle: Earl et al., 1997; Taneja et al., 1998) and/or IVF medium (pig: Boquest et al., 1999; cattle: Van Soom et al., 1998), obtaining an improvement in the blastocyst formation rate. The use of GSH during sperm preparation could be beneficial to membrane stabilization of the spermatozoa and the protection of sperm from free radical damage, and could thus help subsequent fertilization and development.

Goat oocytes have significantly improved IVF rates when spermatozoa are capacitated with ionomycin (Wang et al., 2002). Ionomycin is a calcium ionophore that can increase Ca²⁺ cycling across phospholipid membranes and induce the acrosome reaction (Ball et al., 1983). Wang et al. (2002), studying various factors affecting the effectiveness of the IVM–IVF system of goat oocytes, concluded that spermatozoa treated with heparin plus 100–200nM of ionomycin gave significantly higher fertilization rates compared with the conventional goat sperm treatment of heparin alone.

The aim of this study was to improve in vitro embryo development of prepubertal goat oocytes by studying the effect of adding 400 µM cysteamine to IVM medium, 1 mM GSH to the IVF medium and 200 nM ionomycin to the sperm capacitation medium.

Materials and methods

Oocyte collection

We obtained ovaries from prepubertal (approximately 2 months old) goats from a local slaughterhouse and transported them at 37°C in Dulbecco’s phosphate-buffered saline (PBS; P-4417, Sigma Chemical, St Louis, MO, USA) supplemented with 50 µg/ml gentamicin. Oocytes were recovered by cutting the surface of ovaries with a razor blade in a 60 mm culture dish with TCM199 (M-2520; Sigma, USA), supplemented with 2.2 mg/ml NaHCO₃ and 50 µg/ml gentamicin. We selected only oocytes with one or more complete layers of unexpanded cumulus cells and homogeneous cytoplasm.

In vitro maturation of oocytes

The oocyte maturation medium was TCM199 (M-7528; Sigma, USA) supplemented with 275 µg/ml sodium pyruvate (P-3662; Sigma, USA), 146 µg/ml l-glutamine (G-5763; Sigma, USA), 10% (v/v) steer serum, 10 µg/ml o-LH (L-5269; Sigma, USA), 10 µg/ml o-FSH (Ovagen, Immuno Chemicals Products, Auckland, New Zealand), 1 µg/ml 17β-estradiol (E-2257; Sigma, USA) and 50 µg/ml gentamicin. A group of oocytes were supplemented with 400 µM cysteamine (M-9768; Sigma, USA). The cumulus–oocyte complexes were culture in groups of 20–25 in 100 µl microdrops of maturation medium and incubated for 27 h at 38.5°C in a humidified atmosphere of 5% CO₂ in air under mineral oil (M-8410; Sigma, USA).

Sperm preparation and capacitation

The oocytes were inseminated with fresh semen, at the end of the maturation period. We collected ejaculates from two Murciano-Granadino bucks of proven fertility into artificial vaginas and transported them at 37–38°C within 30 min to the laboratory. The motility of sperm cells was evaluated under an inverted microscope and the motile sperm fraction was separated by swim-up (Parrish et al., 1986). Seventy microlitres of semen was placed in each of several conical tubes under 2 ml Defined Medium (Brackett & Oliphant, 1975) as modified by Younis et al. (1991) and referred to here as mDM, and incubated for 45–60 min in a humidified atmosphere of 5% CO₂ in air at 38.5°C. After incubation, 600 µl from the top of each tube containing highly motile spermatozoa was removed and pooled in a sterile 15 ml centrifuge tube and centrifuged at 200 g for 10 min.

After discarding the supernatant, the resulting sperm pellet was treated in one of two ways: (1) the sperm pellet was resuspended 1:1 (v:v) with mDM medium containing heparin (heparin-sodium salt; 170 UI/mg; final concentration 50 µg/ml of heparin) and incubated in a humidified air atmosphere of 5% CO₂ at 38.5°C (final concentration approximately 84 × 10⁶ sperm/ml) for 45–60 min (heparin group) or (2) the sperm pellet was resuspended 1:1 (v:v) with mDM medium containing 20 µg/ml heparin, 1 mM 8-Br-cAMP and 400 nM ionomycin for 15 min (ionomycin group; final concentration 10 µg/ml heparin, 0.5 mM 8-Br-cAMP and 200 nM ionomycin).
In vitro fertilization of oocytes

After maturation, groups of 20 oocytes were transferred into 80 µl fertilization microdrops of modified Tyrode’s medium (TALP), as described by Parrish et al. (1986), supplemented with 1 µg/ml hypotaurine (H-1384; Sigma, USA). After capacitation, sperm concentration was assessed with a haemocytometer, and an aliquot (5 µl) of the sperm suspension added to the fertilization microdrops (final concentration 3.5 × 10^6 sperm/ml). Oocytes and sperm were incubated for 24 h in a humidified atmosphere of 5% CO2 in air at 38.5°C.

Evaluation of oocytes after IVM and IVF

To evaluate the nuclear stage after IVM, a sample of oocytes was fixed in ethanol (90%):acetic acid (3:1 v/v) after mechanically denuding the oocytes in a 3% sodium citrate solution. After 24–48 h, fixed oocytes were stained with 1% lacmoid (L-7512; Sigma, USA) in 45% acetic acid solution. The oocytes were examined by phase-contrast microscopy. We measured oocyte maturation by the percentage of oocytes reaching the metaphase II (MII) stage.

To evaluate the pronuclear stage after 17 h of IVF a sample of oocytes was processed in the same way as the oocytes fixed after IVM. Oocytes with a sperm tail in the cytoplasm were considered to be fertilized and classified into one of three groups: 2PN (female pronucleus, male pronucleus and one sperm tail; normal fertilization), polyspermy (two or more sperm tails in the cytoplasm with condensed heads or two or more decondensed heads in the cytoplasm) and asynchrony (female pronucleus and a condensed sperm head).

In vitro embryo culture

At 24 h after insemination, the oocytes were washed in the culture medium with the aid of a fine pipette to separate oocytes from any sperm cells. Groups of 20–25 presumptive zygotes were cultured in vitro for 7 days (8 days post-insemination; day 0 = the day of insemination) in 20–25 µl microdrops (1 µl culture medium per embryo) under mineral oil in a humidified atmosphere of 5% CO2, 5% O2 and 90% N2 at 38.5°C. A semi-defined two-step culture system with G1.2/G2.2 media (Gardner & Lane, 1997) was used for embryo culture. Embryos were placed in G1.2 for 3 days and then moved to G2.2 for another 4 days. After 24 h in culture (that is, 48 h post-insemination), 10% (v/v) fetal bovine serum (FBS, Life Technologies) was added to the microdrops (0.1 µl serum per embryo).

At the end of the culture period, we assessed total cell number of embryos with fluorescence microscopy after Hoechst staining and recorded the percentage of total embryos, morulae (embryos with 16 or more cells and without a blastocoele) and blastocysts (embryos with 60 or more cells with blastocoele formation).

Statistical analysis

We calculated differences among treatment groups by means of chi-square analysis or Fisher’s exact test where appropriate. We calculated overall chi-square and found it significant before performing the Fisher’s exact test to detect differences between treatment groups, using Graph Pad In Stat (version 3.01 for Windows 95, Graph Pad Software, San Diego, CA, USA). Differences with a probability value of 0.05 or less were considered significant.

Experimental design

Experiment 1

We analysed the effect of adding 1 mM (0.3 mg/ml) GSH to the IVF medium of oocytes matured with 400 µM cysteamine compared with oocytes matured with cysteamine but without GSH supplementation and a control group. The control group was a sample of oocytes matured and fertilized in the absence of both cysteamine and GSH. In this experiment spermatozoa were capacitated with our conventional protocol (heparin).

Experiment 2

Experiment 2 was designed based on the results obtained in experiment 1. We analysed the effect of sperm capacitation with ionomycin or heparin on IVF and embryo development of prepubertal goat oocytes. According to the results of experiment 1, the oocytes were matured and fertilized in the presence of 400 µM cysteamine and 1 mM GSH, respectively.

Results

Experiment 1

Table 1 shows the nuclear stage after IVM of 220 prepubertal goat oocytes. The percentage of oocytes reaching the MII stage was significantly higher when cysteamine was added to IVM medium (82.72%) compared with oocytes matured with cysteamine but without GSH supplementation and a control group (53.63%; p < 0.0001).

Table 2 shows the IVF parameters of 424 IVM oocytes. There were significant differences in the total fertilized oocytes and oocytes with 2 PN among treatments. The percentages of total fertilized oocytes with 2 PN were significantly higher in oocytes supplemented with cysteamine and GSH (40.26% and 30.20%, respectively) than in oocytes with cysteamine (27.97%, p < 0.04, and 16.08%, p < 0.007, respectively).
Table 1 Effect of cysteamine addition to the IVM medium on nuclear maturation of prepubertal goat oocytes (seven replicates)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total oocytes</th>
<th>GV n (%)</th>
<th>GVBD n (%)</th>
<th>MI n (%)</th>
<th>A–TI n (%)</th>
<th>MII n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 µM cysteamine</td>
<td>110</td>
<td>9 (8.18)</td>
<td>4 (3.63)</td>
<td>38 (34.54)</td>
<td>0</td>
<td>59 (53.63)</td>
</tr>
<tr>
<td>400 µM cysteamine</td>
<td>110</td>
<td>0</td>
<td>0</td>
<td>19 (17.27)</td>
<td>0</td>
<td>91 (82.72)</td>
</tr>
</tbody>
</table>

GV, germinal vesicle; GVBD, germinal vesicle breakdown; MI, metaphase I; A–TI, anaphase–telophase I transition; MII, metaphase II.

Values in the same column with different letters differ significantly ($p < 0.05$).

Table 2 Effect of cysteamine addition to the IVM medium and GSH to the IVF medium on in vitro fertilization of prepubertal goat oocytes (seven replicates)

<table>
<thead>
<tr>
<th>Fertilized oocytes</th>
<th></th>
<th>2PN n (%)</th>
<th>Asynchronous n (%)</th>
<th>Polyspermic n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>132</td>
<td>22 (16.66)</td>
<td>1 (0.76)</td>
<td>7 (5.30)</td>
</tr>
<tr>
<td>400 µM cysteamine GSH−</td>
<td>143</td>
<td>40 (27.97)</td>
<td>23 (16.08)</td>
<td>17 (11.89)</td>
</tr>
<tr>
<td>400 µM cysteamine GSH+</td>
<td>149</td>
<td>60 (40.26)</td>
<td>45 (30.20)</td>
<td>14 (9.40)</td>
</tr>
</tbody>
</table>

PN, pronucleus. Control group: oocytes matured without cysteamine and without GSH on IVF medium.

Values in the same column with different letters differ significantly ($p < 0.05$).

Table 3 Effect of cysteamine addition to the IVM medium and GSH to the IVF medium on embryo development of prepubertal goat oocytes (seven replicates)

<table>
<thead>
<tr>
<th>Embryo development at day 8 post-insemination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inseminated oocytes</td>
</tr>
<tr>
<td>Control group</td>
</tr>
<tr>
<td>400 µM cysteamine GSH−</td>
</tr>
<tr>
<td>400 µM cysteamine GSH+</td>
</tr>
</tbody>
</table>

Control group: oocytes matured without cysteamine and without GSH on IVF medium.

Percentages calculated from total embryos.

Values in the same column with different letters differ significantly ($p < 0.05$).

respectively) and oocytes in the control group (16.66%, $p < 0.0001$, and 10.61%, $p < 0.0002$, respectively).

Table 3 shows the rates of cleavage and development to the blastocyst stage of oocytes in the control group, oocytes supplemented with cysteamine and GSH, and oocytes matured with cysteamine. The percentage of total embryos obtained after 8 days of culture was significantly higher in the group supplemented with cysteamine and GSH (30.62%) than in oocytes matured with cysteamine (16.92%; $p < 0.0003$) and oocytes in the control group (8.09%; $p < 0.0001$). Also the percentage of embryos developed beyond the 8-cell stage was significantly higher in oocytes of the cysteamine + GSH group (22.45%) than in those from the other two groups (6.98%, $p < 0.002$, and 3.84%, $p < 0.0001$ for oocytes matured with cysteamine and the control group, respectively).

Experiment 2

Table 4 shows that the percentage of total fertilized oocytes was significantly higher in the group of spermatozoa capacitated with ionomycin (52.21%) than with heparin (38.62%; $p < 0.0007$). Also the percentage of oocytes with 2PN was higher in the ionomycin group (37.17%) than in the heparin group (28.35%, $p < 0.02$).

Table 5 shows the embryo development of 845 oocytes inseminated with sperm capacitated with ionomycin and 668 oocytes inseminated with heparin-capacitated-sperm. After 7 days of culture, the percentage of inseminated oocytes that developed to embryos was 38.69% and 44.91% ($p < 0.02$) for the ionomycin and heparin groups, respectively. However, the percentage of embryos developed beyond the >8-cell stage did not differ between the groups.
Cysteamine, GSH and ionomycin

Table 4 Effect of sperm treatment on the in vitro fertilization of in vitro matured prepubertal goat oocytes (nine replicates)

<table>
<thead>
<tr>
<th>Sperm treatment</th>
<th>Total oocytes</th>
<th>Fertilized oocytes</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ionomycin</td>
<td>339</td>
<td>177 (52.21)</td>
<td>126 (37.17)</td>
<td>11 (3.24)</td>
<td>40 (11.80)</td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>321</td>
<td>124 (38.62)</td>
<td>91 (28.35)</td>
<td>5 (1.56)</td>
<td>28 (8.72)</td>
<td></td>
</tr>
</tbody>
</table>

PN, pronucleus.

Values in the same column with different letters differ significantly ($p < 0.05$).

Table 5 Effect of sperm treatment on the embryo development of in vitro matured prepubertal goat oocytes (nine replicates)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Inseminated oocytes</th>
<th>Total embryos n (%)</th>
<th>&gt;8-cell embryos n (%)</th>
<th>Morulae (M) n (%)</th>
<th>Blastocysts (B) n (%)</th>
<th>M + B n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ionomycin</td>
<td>845</td>
<td>327 (38.69)</td>
<td>40 (12.23)</td>
<td>5 (1.52)</td>
<td>7 (2.14)</td>
<td>12 (3.66)</td>
</tr>
<tr>
<td>Heparin</td>
<td>668</td>
<td>300 (44.91)</td>
<td>43 (14.33)</td>
<td>1 (0.33)</td>
<td>5 (1.66)</td>
<td>6 (2.00)</td>
</tr>
</tbody>
</table>

*Percentages calculated from total embryos.

Values in the same column with different letters differ significantly ($p < 0.05$).

Discussion

In experiment 1, our results showed that supplementing the IVM medium with 400 µM of cysteamine significantly improved nuclear maturation, total fertilization and total embryos obtained for prepubertal goat oocytes compared with maturation without cysteamine, but these differences disappeared when we compared the percentage of embryos with more than 8 cells. These results agree with previous results obtained in our laboratory. Thus, Rodriguez-González et al. (2003) observed that 100 µM of cysteamine added to the IVM medium increased intracellular GSH levels and significantly improved the percentages of MPN and embryo development. Urdaneta et al. (2003) concluded when adding 100 and 400 µM of cysteamine to the IVM medium that the higher concentration improved embryo development of prepubertal goat oocytes.

Intracytoplasmic GSH plays a central role in the protection of cells against oxidative and electrophilic stress (Knappen et al., 1999). According to De Matos & Furnus (2000), the high intracytoplasmic bovine oocyte GSH levels obtained after IVM with thiol compounds remain constant after fertilization and disappear later at the 6- to 8-cell embryo stage. In our study, reduction of reactive oxygen species and the presence of a high intracellular content of GSH until the beginning of embryo development could be responsible, at least in part, for the improvement observed in maturation, total fertilization and cleavage rates of oocytes matured in the presence of 400 µM cysteamine. Moreover, when we added GSH to the IVF medium of IVM oocytes with cysteamine, the percentage of total fertilization, zygotes with 2 pronuclei, total embryos and embryos developed beyond 8-cell stage were significantly improved, although these treatments did not affect blastocyst rate. In contrast, some studies have indicated no effect on fertilization (Boquest et al., 1999; Kim et al., 1999) or cleavage (Earl et al., 1997; Taneja et al., 1998; Boquest et al., 1999; Kim et al., 1999) rates with the presence of GSH during sperm–oocyte co-incubation, but all of them observed improvements in blastocyst rates.

In cattle, Kim et al. (1999) have observed that the effect of GSH (1 mM) during IVF on embryo development was bull-dependent. Thus, there was an adverse effect, no effect or a beneficial effect on blastocyst formation depending on the bull used. They hypothesize that the male-dependent effect of GSH during IVF is related to differences in the amounts of reactive oxygen species produced by spermatozoa of particular males. These authors also studied the effect of different concentrations of GSH. They found that 1 mM GSH was the best dose to improve blastocyst production and higher doses (10 mM) adversely affected embryo development. The 1 mM GSH concentration also improved bovine blastocyst rates according to Earl et al. (1997). Nevertheless, in pigs 1 mM could be an excessive dose. Thus, Boquest et al. (1999), using 0.5 mM of GSH, and Jeong & Yang (2001) using 0.98 mM, observed a negative effect on blastocyst development.

Extracellularly, GSH prevents lipid peroxidation of cellular membranes by extracellular reactive oxygen species. Acting as an antioxidant, GSH may have reduced the exposure of both oocytes and spermatozoa...
to oxidative stress at or just prior to fertilization, by removing excessive reactive oxygen species present in the insemination medium. Thus, the addition of GSH to IVF medium could be beneficial for membrane stabilization of sperm, oocytes and early embryos. GSH has been detected in the oviductal fluid protecting gametes and embryos (Gardiner et al., 1998).

In our study, supplementation with cysteamine and GSH for IVM and IVF culture media improved fertilization and embryo development. The effect of these compounds could be to increase intracellular GSH levels and also to protect oocytes, zygotes and early embryos against reactive oxygen species. According to Armstrong (2001), oocytes from juvenile donors and the embryos derived from them appear less robust and may be less tolerant to suboptimal handling and in vitro culture conditions than are oocytes from adult females. Thus, developmental deficiencies of the oocytes of prepubertal females may be exacerbated under suboptimal culture conditions. However, embryo development up to blastocyst stage has not been improved by the culture media analysed in this study. Rizos et al. (2002) showed that the percentage of blastocysts obtained is related to the quality of oocytes, and the blastocyst quality is regulated by the culture conditions.

In experiment 2, our data showed that using fresh ejaculates, oocytes inseminated with sperm treated with ionomycin have significantly improved percentages of total and normal fertilization compared with sperm treated with heparin. Ionomycin also improved fertilization rates in the horse (Alm et al., 2001) and adult goats (Wang et al., 2002). As is well known, ionomycin belongs to the calcium ionophore molecule family, and they have been described as potent sperm capacitors. Moreover, it should be pointed out that in our study the group of oocytes inseminated with sperm treated with 50 µg/ml of heparin gave a greater percentage of total embryos than normal fertilized oocytes while in the group of oocytes inseminated with sperm treated with ionomycin the two rates were similar. This fact may be due to the cleavage of abnormal fertilized oocytes in the group inseminated with sperm treated with heparin.

In our study, the oocytes obtained from prepubertal goat ovaries recovered from a commercial slaughterhouse, independently of the oocyte and sperm treatment used, showed a low embryo developmental competence. Although the birth of live calves (Khatir et al., 1998), lambs (O’Brien et al., 1997; Dattena et al., 2000) and piglets (Marchal et al., 2001), has occurred following IVM, IVF and in vitro culture of oocytes obtained from non-stimulated prepubertal donors, it seems that these oocytes have cytoplasmic deficiencies that result in abnormal fertilization and/or their low developmental competence (reviewed by Armstrong, 2001). In our laboratory, Villamediana et al. (2001) found a high number of haploid embryos after IVM and IVF oocytes from prepubertal goats, suggesting that it was due to a deficient cytoplasmic maturation of oocytes, which inhibits sperm head decondensation. In cattle, Salamone et al. (2001), studying cytoplasmic biochemical parameters, showed that the activities of MPF (maturation promoting factor) and MAPK (mitogen-activated protein kinase) and the relative amount of IP3R (inositol 1,4,5-trisphosphate receptor), a mediator of calcium oscillations, were substantially lower in calf compared with adult oocytes. These findings suggest that the low developmental competence of prepubertal oocytes may be attributable to deficiencies in cytoplasmic mechanisms required for oocyte activation. Moreover, Oropeza et al. (2004) observed lower blastocyst development in oocytes recovered by OPU from 6- to 12-month-old calves compared with cow oocytes. These authors found differences in mRNA expression of developmentally important genes (RA for Glut-1; RA for e IF1A; and RA for IGF-1) between calf and adult 2- to 16-cell embryos. These authors concluded that the reduced developmental competence of oocytes from prepubertal calves is attributed to a deficient expression of facilitative glucose transporters and insufficient protein translation.

In conclusion, supplementation with cysteamine (400 µM) to IVM and GSH (1 mM) to IVF culture media improved normal fertilization and embryo development of prepubertal goat oocytes. Fresh goat spermatozoa treated with ionomycin increased the percentage of oocytes fertilized and zygotes with a male pronucleus. However, cysteamine, GSH and ionomycin did not improve blastocyst development.

Acknowledgement

This study was supported by MCYT (grant AGL2000-0353).

References


